Optometry Times

Optometry Times Practical chairside advice Posting Policy:
Thank you for liking the official Optometry Times page. We're glad you're here.
(1)

We are committed to creating a community that encourages self-expression and mirrors the values of Optometry Times including respect for the rights, dignity, and property of others. We ask all fans to do their part to help us achieve the goal. In doing that, we ask you not to post content that:
-is threatening, abusive, obscene, indecent, or objectionable.
-is deceptive, false, or misleading
-viol

ates the intellectual property rights of other people
-is illegal
-references a third party website or is self-promoting spam
-is inappropriate, offensive, or hateful
We reserve the right to remove any content or block users that violate our community guidelines, or that we determine are otherwise offensive to our community. All content must also comply with Facebook's policies as well. We would be sorry to see you go, but if you change your mind and no longer want to like our page, please feel free to "unlike" our page.

As Cataract Awareness Month begins, Optometry Times is highlighting the critical role optometrists play in the early det...
06/03/2026

As Cataract Awareness Month begins, Optometry Times is highlighting the critical role optometrists play in the early detection, monitoring, and management of cataracts.

Follow along throughout the month for expert perspectives, clinical insights, and coverage focused on helping eye care professionals optimize patient outcomes.

https://hubs.li/Q04jY50G0

06/03/2026

Kaleb Abbott, OD, MS, suggested that there are a few other misnomers in the eye care professional’s vocabulary, including… ocular surface disease?

You can find the episode on OptometryTimes.com, YouTube, Apple Podcasts, Spotify, and wherever else you get your podcasts!

06/03/2026

Episode 4 is live! Kaleb Abbott discussed why the term “artificial tears” needs to be replaced in the clinic.

You can find the episode on OptometryTimes.com, YouTube, Apple Podcasts, Spotify, and wherever else you get your podcasts!

In The Independent Advantage’s first season, conversations with Kevin J. Kovach, MD, and Giannie Castellanos, OD, center...
05/29/2026

In The Independent Advantage’s first season, conversations with Kevin J. Kovach, MD, and Giannie Castellanos, OD, centered on how optometrists can thoughtfully select and collaborate with ophthalmologists to protect and enhance patient trust and clinical outcomes. With conversations led by Diana Canto-Sims, OD, the eye care providers framed referral relationships not as a simple handoff, but as a critical extension of the optometrist–patient bond.

In case you missed it, watch highlights from Season 1 here: https://hubs.li/Q04jqrhY0

05/27/2026

Episode 4 of From Paper to Clinic, featuring Kaleb Abbott, OD, MS, airs on Monday, June 1, 2026. Abbott joins host , to discuss the use of the term “artificial tears” in eye care and how an adjustment to that language could help provide a clearer understanding to patients.

You can watch all episodes on the Optometry Times podcasts page, and subscribe to the show on YouTube, Apple Podcasts, Spotify, or on your favorite podcast player.

Academy 2026 Anaheim brings together clinicians, researchers, educators, residents, students, and industry leaders for a...
05/20/2026

Academy 2026 Anaheim brings together clinicians, researchers, educators, residents, students, and industry leaders for an experience dedicated to inspiring excellence in eye care.

Join us September 30 – October 3 in Anaheim, California for four days of cutting-edge education, groundbreaking research, hands-on learning, meaningful connections, and the latest clinical insights.

Early bird registration rates are available now through July 29.
Register now and save at https://hubs.li/Q04h9BqT0.

05/18/2026

Patients can find an evaporative dry eye disease (DED) diagnosis surprising, yet about 86% of those with DED have excessive tear evaporation due to meibomian gland dysfunction.1

Watch the full conversation to learn more about the dry eye cycle and why Dr. Yuna Rapoport starts with MIEBO for her patient Amy and so many others: https://hubs.li/Q04gG8z20

Sponsored by Bausch + Lomb.

MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION
• MIEBO is contraindicated in patients with known hypersensitivity to perfluorohexyloctane
• MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
• Instruct patients to instill one drop of MIEBO into each eye four times daily
• The safety and efficacy in pediatric patients below the age of 18 have not been established
• In pivotal trials, the most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)

Please see full Prescribing Information for MIEBO at https://hubs.li/Q04gG8z20

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://hubs.li/Q04gG8z20 or call 1-800-FDA-1088.

Reference: 1. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31(5):472-478. doi:10.1097/ICO.0b013e318225415a

©2026 Bausch + Lomb
MBO.0075.USA.26

Dry eye management often requires more than selecting the right therapy—it depends on creating treatment plans patients ...
05/14/2026

Dry eye management often requires more than selecting the right therapy—it depends on creating treatment plans patients can understand, commit to, and maintain over time. With an expanding range of diagnostic tools and therapeutic options available, clinicians are increasingly balancing personalized care with practical considerations such as cost, lifestyle, and patient expectations. In this Q&A, Jessilin Quint, OD, MBA, MS, FAAO, shares strategies for improving adherence, building trust through patient communication, avoiding common treatment pitfalls, and leveraging staff support to create a more effective, team-based approach to dry eye care.

Read more: https://hubs.li/Q04gd2G80

"Allergic conjunctivitis (AC) and dry eye disease (DED) are 2 of the most prevalent ocular surface disorders encountered...
05/12/2026

"Allergic conjunctivitis (AC) and dry eye disease (DED) are 2 of the most prevalent ocular surface disorders encountered in clinical practice, with affected patients seeking relief from bothersome ocular signs and symptoms that negatively impact visual function and quality of life. With the onset of spring and throughout summer and fall, optometrists may see an increasing number of patients presenting with complaints of eye irritation, redness, watering eyes, itchiness, and visual disturbances associated with AC," writes Rodolfo L. Rodriguez, OD, DipABO.

Read the article: https://hubs.li/Q04ghYpf0

04/30/2026

Patients can find an evaporative dry eye disease (DED) diagnosis surprising, yet about 86% of those with DED have excessive tear evaporation due to meibomian gland dysfunction.1

Watch the full conversation to learn more about the dry eye cycle and why Dr. Yuna Rapoport starts with MIEBO for her patient Amy and so many others: https://hubs.li/Q04f2MhD0

Sponsored by Bausch + Lomb.

MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION
• MIEBO is contraindicated in patients with known hypersensitivity to perfluorohexyloctane
• MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
• Instruct patients to instill one drop of MIEBO into each eye four times daily
• The safety and efficacy in pediatric patients below the age of 18 have not been established
• In pivotal trials, the most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)

Please see full Prescribing Information for MIEBO at https://hubs.li/Q04f2MhD0

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://hubs.li/Q04f2MhD0 or call 1-800-FDA-1088.

Reference: 1. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31(5):472-478. doi:10.1097/ICO.0b013e318225415a

©2026 Bausch + Lomb
MBO.0075.USA.26

Address

24950 Country Club Boulevard, Ste 200
North Olmsted, OH
44070

Telephone

+14402438100

Website

Alerts

Be the first to know and let us send you an email when Optometry Times posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Optometry Times:

Shortcuts

Share

Category